Get the Stockscreener App
13.99
1.89%
-0.27
Seres Therapeutics Inc stock is traded at $13.99, with a volume of 47,064.
It is down -1.89% in the last 24 hours and up +30.69% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$14.26
Open:
$14
24h Volume:
47,064
Relative Volume:
0.42
Market Cap:
$122.17M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-699.50
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
-3.72%
1M Performance:
+30.69%
6M Performance:
-17.21%
1Y Performance:
-44.48%
1-Day Range:
$13.38
$14.10
1-Week Range:
$12.15
$15.40
52-Week Range:
$6.53
$26.40
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
13.99 | 124.52M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Why is Seres Therapeutics Inc. stock attracting strong analyst attentionRetirement Planning Entry Points For Consistent Profits - jammulinksnews.com
What makes Seres Therapeutics Inc. stock price move sharplyEarnings Report Opportunities To Watch Now - jammulinksnews.com
Is Seres Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - metal.it
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough - Seeking Alpha
Why Seres Therapeutics Inc. stock attracts strong analyst attentionEntry Zone Strategy for Consistent Profit Shared - metal.it
What institutional investors are buying Seres Therapeutics Inc. stockPhenomenal wealth increase - jammulinksnews.com
How many analysts rate Seres Therapeutics Inc. as a “Buy”Build wealth with reliable stock picks - jammulinksnews.com
Is Seres Therapeutics Inc. a growth stock or a value stockAchieve rapid returns with smart investment plans - jammulinksnews.com
How does Seres Therapeutics Inc. compare to its industry peersAchieve exceptional returns with expert guidance - jammulinksnews.com
Will Seres Therapeutics Inc. Recover After Recent DeclineStock Market Entry Timing Signals Revealed - metal.it
What is the dividend policy of Seres Therapeutics Inc. stockSkyrocketing returns - jammulinksnews.com
When is Seres Therapeutics Inc. stock expected to show significant growthBreakout profit opportunities - jammulinksnews.com
Should I hold or sell Seres Therapeutics Inc. stock in 2025High-octane investment opportunities await - jammulinksnews.com
What are Seres Therapeutics Inc. company’s key revenue driversGet expert alerts on market-moving stocks - jammulinksnews.com
Seres Therapeutics announces leadership transition - MSN
Is Seres Therapeutics Inc. a good long term investmentRapid profit acceleration - PrintWeekIndia
Will Seres Therapeutics Inc. stock benefit from AI tech trendsHigh-yield capital appreciation - jammulinksnews.com
What risks could impact Seres Therapeutics Inc. stock performancePhenomenal capital appreciation - jammulinksnews.com
What analysts say about Seres Therapeutics Inc. stockFree Stock Market Beginners Guide - PrintWeekIndia
Why Seres Therapeutics Inc. stock is on top investor watchlistsHigh-yield capital appreciation - jammulinksnews.com
What institutions are buying Seres Therapeutics Inc. stock nowBreakneck growth rates - jammulinksnews.com
What drives Seres Therapeutics Inc. stock priceUnprecedented growth rates - Autocar Professional
Seres Therapeutics Announces CEO Resignation and New Appointments - The Globe and Mail
Seres Therapeutics Inc. Stock Analysis and ForecastFree Consultation - Autocar Professional
Seres Therapeutics Soars 10.98% on Leadership Transition - AInvest
Seres Therapeutics shares rise 3.97% premarket after appointing new CEOs and discussing capital raise. - AInvest
Seres Therapeutics stock jumps after naming co-CEOs By Investing.com - Investing.com Canada
Seres Therapeutics (MCRB) Announces Transition in Executive Lead - GuruFocus
Seres Therapeutics Announces Leadership Transition - The Manila Times
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 - The Manila Times
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):